Market Overview

AstraZeneca's Lynparza Ovarian Cancer Drug shows Investigator-Assessed Progression-Free Survival Of 19.1 Months, 30.2M Months PFS Based On Independent Central Review

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: FDA

 

Related Articles (AZN)